KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardlytics (CDLX) Gains from Investment Securities (2017 - 2025)

Cardlytics (CDLX) has disclosed Gains from Investment Securities for 9 consecutive years, with $6.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 209.33% year-over-year to $6.1 million, compared with a TTM value of $6.2 million through Dec 2025, up 521.54%, and an annual FY2025 reading of $6.2 million, up 521.54% over the prior year.
  • Gains from Investment Securities was $6.1 million for Q4 2025 at Cardlytics, up from -$8.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $19.2 million in Q4 2023 and bottomed at -$24.2 million in Q2 2023.
  • Average Gains from Investment Securities over 5 years is $185850.0, with a median of $139500.0 recorded in 2021.
  • The sharpest move saw Gains from Investment Securities tumbled 3370.29% in 2022, then surged 542.76% in 2024.
  • Year by year, Gains from Investment Securities stood at $2.6 million in 2021, then soared by 48.55% to $3.9 million in 2022, then surged by 388.28% to $19.2 million in 2023, then plummeted by 129.23% to -$5.6 million in 2024, then surged by 209.33% to $6.1 million in 2025.
  • Business Quant data shows Gains from Investment Securities for CDLX at $6.1 million in Q4 2025, -$8.0 million in Q3 2025, and $8.0 million in Q2 2025.